Article | November 9, 2018

The Connected Process

Source: MilliporeSigma
pharm mfg factory

“As seen in the Medicine Maker”

In the early days of biomanufacturing, companies focused primarily on approvals, with process optimization being a much lower priority. This remained the case while the prices of biologics far outstripped the costs of manufacture, but in the age of biosimilars and cost-conservative payers, companies are now re-examining cost drivers in biologics manufacture. “Today, manufacturing is a strategic imperative and an area for differentiation – an opportunity to look at new technologies that can really drive down costs,” explains Michael Phillips, Director, Next Generation Bioprocessing R&D, at Merck. “Companies are now focusing on how to get more out of their processes, how technologies, such as single use, can help, and looking to implement in-line sensors and analytics. Increasingly, companies are also looking at the potential to connect bioprocesses.”